Symbol | Exchange | Currency |
|---|
Benzinga - ContraFect Corporation (NASDAQ: CFRX) has announced the database lock of its Phase 3 DISRUPT study of exebacase in patients with Staph aureus bacteremia, along with a...
ContraFect Corporation (NASDAQ: CFRX) has announced the database lock of its Phase 3 DISRUPT study of exebacase in patients with Staph aureus bacteremia, along with a summary of...
Investing.com - ContraFect Corp reported on Monday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations. ContraFect Corp announced...
YONKERS, N.Y., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct...
ContraFect Corporation is a late clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa and has demonstrated potent in vivo activity against extensively drug-resistant (XDR) strains. It has developed an, engineered variant of exebacase, known as CF-296. It is conducting further in vitro and in vivo characterization of CF-296 to evaluate the full profile of this compound.
| Average | 5.000 (+8,096.721% Upside) |
| High | 7.000 |
| Low | 3.000 |
| Price | 0.061 |
| No. of Analysts | 2 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 366.60 | 375.20 | 356.00 | -10.60 | -2.81% | 220.06K | London | |||
| 109.12 | 109.70 | 107.20 | -1.08 | -0.98% | 38.49M | London | |||
| 457.40 | 463.50 | 454.20 | -8.50 | -1.82% | 10.70M | London | |||
| 93.55 | 93.86 | 93.02 | +0.13 | +0.14% | 153.41M | London | |||
| 560.00 | 570.00 | 560.00 | -5.00 | -0.89% | 10.89K | London | |||
| 210.90 | 211.50 | 207.80 | -1.40 | -0.66% | 2.90M | London | |||
| 348.40 | 354.40 | 334.80 | +6.40 | +1.87% | 1.28M | London | |||
| 36.90 | 38.00 | 36.52 | -1.26 | -3.30% | 8.28M | London | |||
| 849.20 | 849.40 | 848.80 | 0.00 | 0.00% | 0.00 | London | |||
| 752.40 | 765.00 | 750.60 | -14.60 | -1.90% | 2.51M | London | |||
| 69.20 | 70.40 | 68.10 | -1.20 | -1.71% | 533.67K | London | |||
| 2,120.00 | 2,201.00 | 2,097.00 | -78.0 | -3.55% | 715.31K | London | |||
| 802.00 | 810.00 | 786.00 | -11.00 | -1.35% | 53.23K | London | |||
| 27.34 | 27.56 | 26.98 | -0.38 | -1.37% | 4.93M | London | |||
| 1,700.00 | 1,702.00 | 1,700.00 | 0.00 | 0.00% | 0.00 | London |